Daniel M Scott

This inventor holds 27 USPTO granted patents, plus 3 CIPO patents and 7 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Biogen Idec Ma Inc., Sunesis Pharmaceuticals, Inc., Biogen Ma Inc.. Active years: 1996-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Daniel M Scott. Retrieved from https://idiyas.com/inventor/daniel-m-scott

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 27

% Patents Active = 63.0

CIPO Patents = 3

EPO Patents = 7 (Patent Applications = 3)

Average Co-Inventor Count = 6.2

ph-index = 6

Forward Citations = 130(Granted Patents)

Location History:

Waltham, MA (US) (1996)
Acton, MA (US) (2004 - 2011)
Weston, MA (US) (2003 - 2020)

Company Filing History:

Sunesis Pharmaceuticals, Inc.

Epix Pharmaceuticals, Inc.

Lantheus Medical Imaging, Inc.

Millenium Pharmaceuticals, Inc.

patents

10. 1 out of 855

Millennium Pharmaceuticals Limited

patents

where one patent can have more than one assignee

Years Active: 1996-2020

Loading Chart...

Areas of Expertise:

Bruton's Tyrosine Kinase

Sphingosine Analog

PDK1 Inhibitors

Heterobicyclic Compounds

Heterocyclic Compounds

Cell Adhesion Inhibitors

Diagnostic Imaging

Contrast Agents

Bioactivated Agents

MRI Agents

Binding Molecules

Bicyclic Aryl Compounds

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10577374 - Bruton's tyrosine kinase inhibitors (2020-03-03),

2. 10081646 - Heterobicyclic sphingosine 1-phosphate analogs (2018-09-25),

3. 10030016 - Heterocyclic compounds useful as PDK1 inhibitors (2018-07-24),

4. 9790229 - Bruton's tyrosine kinase inhibitors (2017-10-17),

5. 9708353 - Heterobicyclic sphingosine 1-phosphate analogs (2017-07-18),

6. 9546165 - Heterocyclic compounds useful as PDK1 inhibitors (2017-01-17),

7. 9273028 - Heterocyclic tyrosine kinase inhibitors (2016-03-01),

8. 9249146 - Bruton'S tyrosine kinase inhibitors (2016-02-02),

9. 9181191 - Heterobicyclic sphingosine 1-phosphate analogs (2015-11-10),

10. 9029359 - Heteroaryl Btk inhibitors (2015-05-12),

11. 8785440 - Bruton's tyrosine kinase inhibitors (2014-07-22),

12. 8618042 - Binding molecules and methods of use thereof (2013-12-31),

13. 8546359 - Bicyclic aryl sphingosine 1-phosphate analogs (2013-10-01),

14. 8394356 - Diagnostic imaging contrast agents with extended blood retention (2013-03-12),

15. 8349849 - Heterobicyclic sphingosine 1-phosphate analogs (2013-01-08),

Title: The Innovations of Daniel M. Scott: A Pioneering Inventor in Biochemistry

Introduction

Daniel M. Scott is an accomplished inventor based in Acton, MA, known for his significant contributions to the field of biochemistry. With an impressive portfolio of 27 patents, Scott has made substantial advancements in drug discovery and development, particularly in the realm of targeted therapies.

Latest Patents

Among Scott's latest innovations are two notable patents. The first is focused on Bruton's tyrosine kinase inhibitors, which outlines compounds that serve as effective inhibitors of Btk. This invention encompasses compositions and methods for utilizing these compounds, demonstrating significant potential in treating various diseases. The second patent highlights heterobicyclic sphingosine 1-phosphate analogs. These compounds exhibit agonist activity at specific S1P receptors, functioning as sphingosine analogs that, upon phosphorylation, can modulate receptor activity.

Career Highlights

Daniel M. Scott has made remarkable strides in his career, having worked with renowned companies such as Biogen Idec Massachusetts, Inc. and Sunesis Pharmaceuticals, Inc. His efforts have not only advanced scientific knowledge but have also paved the way for new treatment options in the pharmaceutical industry.

Collaborations

Throughout his career, Scott has collaborated with talented professionals, including Gnanasambandam Kumaravel and Wen-Cherng Lee. These partnerships have been instrumental in driving innovation and developing groundbreaking therapies, reflecting a collaborative spirit that is crucial in the research community.

Conclusion

Daniel M. Scott exemplifies the impact that inventors can have on biochemistry and pharmaceutical advancements. With a strong patent portfolio and collaborations with esteemed colleagues, his work continues to influence the development of innovative treatments, potentially transforming patient care in the future.

Profile summary based on public USPTO records.